Boston Pharmaceuticals, Inc.

Laura Carter

Partha S Chowdhury

Melissa Marie Damschroder

Xiaodong Xiao

Ronald Herbst

Reena Varkey

Stacey Drabic

Qun Du

Ping Tsui

Catherine Ettinger

Jodi Karnell

Brian Michael Naiman

Melissa Damschroder

Partha Chowdhury

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

Growing community of inventors

Ann Arbor, MI, United States of America

Laura Carter